Triple therapy offers hope for hard-to-treat liver cancer
NCT ID NCT07353827
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new combination of treatments for people with a specific liver cancer (intrahepatic cholangiocarcinoma) that cannot be surgically removed. The treatment includes chemotherapy delivered directly to the liver, along with two oral and intravenous drugs. The goal is to see if this combination can shrink tumors and improve survival. About 36 participants will be enrolled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC ARTERIAL INFUSION CHEMOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-san University Cancer Center
Guangzhou, Guangdong, 510080, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Spirulina's secret protein may shield the liver during surgery
- New drug cocktail aims to outsmart untreatable bile duct cancer
- AI could spot liver cancer types and predict survival without needle biopsy
- New drug cocktails aim to stop bile duct cancer return after surgery
- New cocktail of Liver-Directed chemo and immunotherapy targets deadly bile duct cancer
- Anti-Inflammatory drug may boost cancer therapy in bile duct cancer